HRH1 and glaucoma: We found that both systemic administration of maprotiline and locally applied CRISPR-mediated RGC-specific HRH1 inhibition achieve significant neuroprotection and visual function recovery in in vivo mouse models of glaucoma and traumatic ON injury.